A phase 1/2 trial of CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) in advanced solid tumours, run by Carrick Therapeutics Limited, now recruiting.
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies is a phase 1/2 interventional study registered as NCT06600789 by Carrick Therapeutics Limited, with 50 participants planned, started 2024-08-16 and due to reach its primary completion in 2027-03-14. Interventions recorded: CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg).
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.